

Experience with Strama in Sweden

Lars Blad

MD, Inf Dis Specialist

Dep Regional Medical Officer Region Västmanland

Chairman Strama Network


Member Swedish ICG AMR

WHO EURO Consultant on containment of AMR

Collaboration




Figure 3.22. Acinetobacter spp. Percentage (%) of invasive isolates with resistance to carbapenems, by country, EU/EEA countries, 2017




European Centre for Disease Prevention and Control. Surveillance of antimicrobial resistance in Europe – Annual report of the European Antimicrobial Resistance Surveillance Network (EARS-Net) 2017. Stockholm: ECDC; 2018.

Staphylococcus aureus. Percentage (%) of invasive isolates with resistance to meticillin (MRSA), Sweden and EU/EEA population-weighted mean, 2010–2017




centage resitance (%)


Escherichia coli. Percentage (%) of invasive isolates with resistance to third-generation cephalosporins, Sweden and EU/EEA population-weighted mean, 2010–2017



Klebsiella pneumoniae. Percentage (%) of invasive isolates with resistance to carbapenems, Sweden and EU/EEA population-weighted mean, 2010-2017




Enterococcus faecium. Percentage (%) of invasive isolates with resistance to vancomycin, Sweden and EU/EEA population-weighted mean, 2010–2017





European Centre for Disease Prevention and Control. Surveillance of antimicrobial resistance in Europe – Annual report of the European Antimicrobial Resistance Surveillance Network (EARS-Net) 2017. Stockholm: ECDC; 2018.

Antibiotic use Sweden 1987-2017 per age group



Trend of the consumption of antimicrobials in ATC group J01 (antibacterials for systemic use) in the community (primary care sector) in Sweden, Denmark and Norway from 1997 to 2017








- Strama-groups were formed, 1995 in every county
- The County Medical Officers for Communicable Diseases Control have a leading role in these groups which include specialists from different medical fields

 A main objective is to evaluate the use of antibiotics and antibacterial resistance in the region and to improve prescribing patterns

"Champions"...



Sigvard Mölstad, Professor and PHC clinician

Strama's organization


Remit and financing first from government, now from regional health-care providers

National Strama

The local (regional) Strama groups (typically):

- ✓ County medical officer
- ✓ Pharmacist
- ✓ Microbiologist
- ✓ General practitioner
- ✓ Infectious diseases specialist
- Infection control

✓ ENT, paediatrician, geriatrician, dentist...



The overall aims of Strama

Best available treatment to the patient


 To preserve the effectiveness of antibiotics and prevent the emergence and spread of resistant bacteria

Multifaceted approach


- Increase awareness about AMR among professionals, politicians and the public
 - Regular information to Swedish media local data!
 - Campaigns to improve prescribing and avoid unnecessary prescribing
- National and regional meetings to share experiences and ideas and catalyze multisectoral collaboration
- Education and workshops multiple target groups
- Scientific studies; optimize use of old antibiotics, PPS
- Monitoring the international scientific literature and media

Strama coordination and feedback


National coordination has has always been needed but the means have shifted...



Network of local Strama groups




The continuous work of the Strama group



Example: fluoroquinolone resistance in E. coli


Fluoroquinolone-Resistant *E.coli* in Europe, 2001-2006







ResNet 2007: E.coli



Surgical clinic, Sundsvall hospital, antibiotic prescriptions 2006 - 2008 3000 J01MA02 - ciprofloxacin 2500 J01CF05 - flukloxacillin J01FF01 - klindamycin 2000 J01AA02 - doxycyklin J01CE02 - fenoximetylpenicillin (pcV) J01CA04 - amoxicillin 1500 J01AA04 - lymecyklin J01EE01 - sulfametoxazol + trimetoprim 1000 J01MA06 - norfloxacin J01CA08 - pivmecillinam J01AA07 - tetracyklin 500 J01EA01 - trimetoprim

DDD, Defined Daily Doses

0

2006-

KV1

2006-

KV2

2006-

KV3

2006-

KV4

2007-

KV1

2007-

KV2

2007-

KV3

2007-

KV4

2008-

KV1

2008-

KV2


2008-

KV4

2008-


KV3

Fluoroquinolone use (J01M), total (prescriptions and requisitions) 1,4 1,2 Sweden



DDD/1000 inhabitants/day

Sales of antibiotics commonly used to treat lower urinary tract infections in women (sales on prescriptions), age 18-79 years, 2000-2013, prescriptions/1000 women and year; Sweden



National treatment guidelines form the basis

- Written, evidence-based or consensus guidelines are released by MPA, PHA and Strama, means high credibility
- Distributed to all doctors
 - Short pocket and full printed versions

Info in "App" format

Face to face meetings by Stramagroups

Feed-back according to prescription profile per clinic








- **AOM**, 2000, updated 2010
- ■Tonsillitis 2001, updated 2012
- ■Sinusitis, 2005 (update 2019-20)
- ■Lower UTI, 2007, updated 2017
- ■Lower RTI, 2008
- •Skin infections, 2009, updated 2018
- Early warning signs of serious infections in children, 2011







Open benchmarking at all levels (regions, municipalities, GP-station, hospital...)



Some LEAD WORDS – possible success factors

- Local engagement
- Network: bottoms-up, top-down, lateral sharing
- Early and strong government support
- Cooperation multidisciplinary, multisectoral
- Champions
- Credibility
- Adaptability
- Long term perspective

Thank you for your attention!

